Complete response to anti-interleukin-5 biologics in a real-life setting: results from the nationwide Danish Severe Asthma Register

BACKGROUND: Phase III regulatory trials show that anti-interleukin (IL)-5 biologics efficiently reduce exacerbations and the use of maintenance oral corticosteroids (mOCS) in patients with severe eosinophilic asthma. However, patients eligible for these trials differ significantly compared with real...

Descripción completa

Detalles Bibliográficos
Autores principales: Soendergaard, Marianne Baastrup, Hansen, Susanne, Bjerrum, Anne-Sofie, Hilberg, Ole, Lock-Johansson, Sofie, Håkansson, Kjell Erik Julius, Ingebrigtsen, Truls Sylvan, Johnsen, Claus Rikard, Rasmussen, Linda Makowska, von Bülow, Anna, Assing, Karin Dahl, Schmid, Johannes Martin, Ulrik, Charlotte Suppli, Porsbjerg, Celeste
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530888/
https://www.ncbi.nlm.nih.gov/pubmed/36199589
http://dx.doi.org/10.1183/23120541.00238-2022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530888/
https://www.ncbi.nlm.nih.gov/pubmed/36199589
http://dx.doi.org/10.1183/23120541.00238-2022

Ejemplares similares